India Clarifies Injectable Products Cannot Be Regulated as Cosmetics

India's Central Drugs Standard Control Organisation (CDSCO) has now made it explicit that injectable products cannot be classified, marketed, or sold as cosmetics under Indian law. Any product administered via injection falls outside the legal definition of a cosmetic, which is limited to substances intended to be rubbed, poured, sprinkled, sprayed or otherwise applied externally to the human body. As a result, injectable "beauty" treatments marketed as cosmetics sit in a grey zone and face heightened regulatory scrutiny and enforcement risk.

This clarification directly affects IV "beauty drips", glutathione injections, skin-whitening injectables and other aesthetic treatments that have been promoted as cosmetic procedures rather than regulated medicinal products. Clinics, brands and distributors who have relied on cosmetic positioning now need to reassess how these products are classified, marketed, and sold – and how their wider portfolios are exposed to similar shocks as regulators tighten definitions and enforcement.

The immediate pain point is compliance risk. If you operate clinics, aesthetic centres, med-spas, or online beauty platforms offering injectable treatments, you may now be marketing products in a way that conflicts with CDSCO's guidance. That can translate into disrupted services, forced product withdrawals, reputational damage, and potential liability if regulators determine that your injectables should have been treated as drugs or medical treatments rather than cosmetics.

For brands and distributors, the challenge multiplies across SKUs and markets. Product portfolios that stretch across topical cosmetics, ingestible supplements and injectable treatments now have to be evaluated category by category. Marketing claims that were acceptable under a cosmetic framework may need to be revised or withdrawn, and packaging, labelling and advertising must all be brought into line with the new regulatory reality. What looks like a single advisory can quickly become a complex portfolio-wide problem.

Worldover's AI-powered operating system, anchored by the Willow engine, is designed exactly for moments like this. Instead of treating regulatory changes as one-off crises, Worldover continuously monitors, maps and interprets developments across cosmetics, chemicals and adjacent regulated product categories. When a regulator clarifies that injectables are not cosmetics, Worldover can show you which SKUs are affected, where they sit across your global portfolio, and what actions are required to reduce risk.

For cosmetic and chemical brands, that means being able to see, in one place, how fast-changing rules in India, and later in other markets, touch your formulations, claims, packaging and distribution. You can model the impact of new guidance, prioritise high-risk products, and coordinate changes between regulatory, marketing, supply chain and commercial teams. Instead of reacting manually to every new notice, you use a single AI-driven operating system to keep your portfolio continuously aligned with the regulatory environment – in India now, and across new markets as rules evolve.